This research report provides a comprehensive analysis of the Squamous Non-Small Cell Lung Cancer Therapeutics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Squamous Non-Small Cell Lung Cancer Therapeutics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Squamous Non-Small Cell Lung Cancer Therapeutics, challenges faced by the industry, and potential opportunities for market players.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Squamous Non-Small Cell Lung Cancer Therapeutics market presents opportunities for various stakeholders, including Research Center, Hospital. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Squamous Non-Small Cell Lung Cancer Therapeutics market. Additionally, the growing consumer demand present avenues for market expansion.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Squamous Non-Small Cell Lung Cancer Therapeutics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Squamous Non-Small Cell Lung Cancer Therapeutics market.
Market Overview: The report provides a comprehensive overview of the Squamous Non-Small Cell Lung Cancer Therapeutics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., BMS-906024, Buparlisib Hydrochloride), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Squamous Non-Small Cell Lung Cancer Therapeutics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Squamous Non-Small Cell Lung Cancer Therapeutics market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Squamous Non-Small Cell Lung Cancer Therapeutics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Squamous Non-Small Cell Lung Cancer Therapeutics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Squamous Non-Small Cell Lung Cancer Therapeutics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Squamous Non-Small Cell Lung Cancer Therapeutics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Squamous Non-Small Cell Lung Cancer Therapeutics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Squamous Non-Small Cell Lung Cancer Therapeutics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Squamous Non-Small Cell Lung Cancer Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Market segment by Application
Research Center
Hospital
Clinic
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Squamous Non-Small Cell Lung Cancer Therapeutics, market overview.
Chapter 2: Global Squamous Non-Small Cell Lung Cancer Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Squamous Non-Small Cell Lung Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Overall Market Size
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2023 VS 2030
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Squamous Non-Small Cell Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2023
3.5 Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Markets, 2023 & 2030
4.1.2 BMS-906024
4.1.3 Buparlisib Hydrochloride
4.1.4 FP-1039
4.1.5 Ipilimumab
4.1.6 JNJ-42756493
4.1.7 Lenvatinib
4.1.8 Others
4.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2024
4.2.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2025-2030
4.2.3 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2023 & 2030
5.1.2 Research Center
5.1.3 Hospital
5.1.4 Clinic
5.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2024
5.2.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2025-2030
5.2.3 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2023 & 2030
6.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2024
6.2.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2025-2030
6.2.3 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030
6.3.2 US Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.3.3 Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.3.4 Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030
6.4.2 Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.3 France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.4 U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.5 Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.6 Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.7 Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.4.8 Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030
6.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.5.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.5.4 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.5.5 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.5.6 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030
6.6.2 Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.6.3 Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030
6.7.2 Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.7.3 Israel Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.7.4 Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
6.7.5 UAE Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2019-2030
7 Squamous Non-Small Cell Lung Cancer Therapeutics Companies Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Company Summary
7.1.2 Ascenta Therapeutics, Inc. Business Overview
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.1.5 Ascenta Therapeutics, Inc. Key News & Latest Developments
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Company Summary
7.2.2 AstraZeneca Plc Business Overview
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.2.5 AstraZeneca Plc Key News & Latest Developments
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Company Summary
7.3.2 AVEO Pharmaceuticals, Inc. Business Overview
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.3.5 AVEO Pharmaceuticals, Inc. Key News & Latest Developments
7.4 Bayer AG
7.4.1 Bayer AG Company Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.4.5 Bayer AG Key News & Latest Developments
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Company Summary
7.5.2 BIND Therapeutics, Inc. Business Overview
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.5.5 BIND Therapeutics, Inc. Key News & Latest Developments
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Company Summary
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.6.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Company Summary
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.7.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Company Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.8.5 Eli Lilly and Company Key News & Latest Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Company Summary
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Company Summary
7.10.2 Five Prime Therapeutics, Inc. Business Overview
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.10.5 Five Prime Therapeutics, Inc. Key News & Latest Developments
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Company Summary
7.11.2 Genentech, Inc. Business Overview
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.11.5 Genentech, Inc. Key News & Latest Developments
7.12 Incyte Corporation
7.12.1 Incyte Corporation Company Summary
7.12.2 Incyte Corporation Business Overview
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.12.5 Incyte Corporation Key News & Latest Developments
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Company Summary
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.13.5 Johnson & Johnson Key News & Latest Developments
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Company Summary
7.14.2 MacroGenics, Inc. Business Overview
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.14.5 MacroGenics, Inc. Key News & Latest Developments
7.15 Novartis AG
7.15.1 Novartis AG Company Summary
7.15.2 Novartis AG Business Overview
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.15.5 Novartis AG Key News & Latest Developments
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Company Summary
7.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.16.5 Oncogenex Pharmaceuticals, Inc. Key News & Latest Developments
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Company Summary
7.17.2 PsiOxus Therapeutics Limited Business Overview
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.17.5 PsiOxus Therapeutics Limited Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics in Global Market
Table 5. Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Companies, 2019-2024
Table 8. Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2025-2030
Table 30. Ascenta Therapeutics, Inc. Company Summary
Table 31. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 32. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 33. Ascenta Therapeutics, Inc. Key News & Latest Developments
Table 34. AstraZeneca Plc Company Summary
Table 35. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 36. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 37. AstraZeneca Plc Key News & Latest Developments
Table 38. AVEO Pharmaceuticals, Inc. Company Summary
Table 39. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 40. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 41. AVEO Pharmaceuticals, Inc. Key News & Latest Developments
Table 42. Bayer AG Company Summary
Table 43. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 44. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 45. Bayer AG Key News & Latest Developments
Table 46. BIND Therapeutics, Inc. Company Summary
Table 47. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 48. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 49. BIND Therapeutics, Inc. Key News & Latest Developments
Table 50. Boehringer Ingelheim GmbH Company Summary
Table 51. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 52. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 53. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 54. Bristol-Myers Squibb Company Company Summary
Table 55. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 56. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 57. Bristol-Myers Squibb Company Key News & Latest Developments
Table 58. Eli Lilly and Company Company Summary
Table 59. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 60. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 61. Eli Lilly and Company Key News & Latest Developments
Table 62. F. Hoffmann-La Roche Ltd. Company Summary
Table 63. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 64. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 65. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 66. Five Prime Therapeutics, Inc. Company Summary
Table 67. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 68. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 69. Five Prime Therapeutics, Inc. Key News & Latest Developments
Table 70. Genentech, Inc. Company Summary
Table 71. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 72. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 73. Genentech, Inc. Key News & Latest Developments
Table 74. Incyte Corporation Company Summary
Table 75. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 76. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 77. Incyte Corporation Key News & Latest Developments
Table 78. Johnson & Johnson Company Summary
Table 79. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 80. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 81. Johnson & Johnson Key News & Latest Developments
Table 82. MacroGenics, Inc. Company Summary
Table 83. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 84. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 85. MacroGenics, Inc. Key News & Latest Developments
Table 86. Novartis AG Company Summary
Table 87. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 88. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 89. Novartis AG Key News & Latest Developments
Table 90. Oncogenex Pharmaceuticals, Inc. Company Summary
Table 91. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 92. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 93. Oncogenex Pharmaceuticals, Inc. Key News & Latest Developments
Table 94. PsiOxus Therapeutics Limited Company Summary
Table 95. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 96. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 97. PsiOxus Therapeutics Limited Key News & Latest Developments
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type in 2023
Figure 2. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Application in 2023
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 8. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 9. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 10. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 12. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 14. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 15. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 16. US Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 20. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 21. France Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 28. China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 32. India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 34. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2030
Figure 37. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 41. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
